VCEL Vericel

Vericel to Present at Multiple Upcoming Investor Conferences

Vericel to Present at Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences:

  • TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025
  • Canaccord Genuity 2025 Musculoskeletal Conference on Monday, March 10, 2025
  • Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025

A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: .

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit .

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.

Investor Contact:

Eric Burns



+1 (734) 418-4411



EN
04/03/2025

Underlying

VCELVericel

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vericel

 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025

Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at . Please vi...

April 24, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Present at Multiple Upcoming Investor Conferences

Vericel to Present at Multiple Upcoming Investor Conferences CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025Canaccord Genuity 2025 Musculoskeletal Conference on Monday, March 10, 2025Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025 A webcast of the presentations will be available...

March 4, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth Quarter Gross Margin of 78%, Adjusted EBITDA Margin of 40%, and Net Income of $19.8 Million Mid-Term Profitability Targets Increased to Gross Margin in the High-70% Range and Adjusted EBITDA Margin in the High-30% Range Strong MACI Arthro Key Launch Indicators, with Approximately 250 MACI Arthro Surgeons Trained to Date 2025 F...

February 27, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results ...

Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025 CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations sect...

February 13, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel Announces Preliminary 2024 Financial Results, 2025 Financial G...

Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Quarterly MACI Implants, Surgeons, and Biopsies Since Launch and Strong Early MACI Arthro Launch Indicators Record Fourth Quarter Gross Margin of Approximately 77% and Adjusted EBITDA Margin of 39% 2025 Total Revenue Guidance of 20% to 23% Growth Mid-Term Profitability Tar...

January 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch